In a number of European countries (e.g. Belgium), analgesic nephropathy continues to be a highly prevalent renal disease, whereas in other countries (e.g. Sweden) the problem has been resolved after legislative measures were taken.
In still other countries, e.g. France, the official prevalence of analgesic nephropathy has always been low.
The aim of the present study is to detect whether specific legislation in particular countries has played a role in the prevalence of analgesic nephropathy.
Hence, we compared analgesic legislation in Belgium, France and Sweden, and then compared it with the respective sales data of non-narcotic analgesics and with the prevalence data of analgesic nephropathy in the dialysis population.
Each investigated country represents a different evolution pattern in the prevalence of analgesic nephropathy.
This study indicates that legislation restricting the overthe-counter availability of the majority of analgesic components and resulting in the absence of analgesic mixtures-containing two analgesic substances and one potentially addictive substance-on the market, has effectively resulted in a substantially lower prevalence of analgesic nephropathy.
Mots-clés Pascal : Néphropathie, Iatrogène, Analgésique, Toxicité, Prescription médicale, France, Europe, Epidémiologie, Homme, Suède, Belgique, Analyse corrélation, Appareil urinaire pathologie, Rein pathologie, Médicament vente libre, Dispensation
Mots-clés Pascal anglais : Nephropathy, Iatrogenic, Analgesic, Toxicity, Medical prescription, France, Europe, Epidemiology, Human, Sweden, Belgium, Correlation analysis, Urinary system disease, Renal disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0199205
Code Inist : 002B02U06. Création : 09/06/1995.